Literature DB >> 8169388

Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention.

A A Ries1, J G Wells, D Olivola, M Ntakibirora, S Nyandwi, M Ntibakivayo, C B Ivey, K D Greene, F C Tenover, S P Wahlquist.   

Abstract

An epidemic of Shigella dysenteriae type 1 infections has affected Africa since 1979. Reported dysentery cases increase sharply in Burundi during September through December. Of stool samples from 189 patients reporting bloody diarrhea in November 1990, a pathogen was identified in 123 (65%). The pathogen was S. dysenteriae type 1 in 82 (67%). All S. dysenteriae type 1 isolates were resistant to ampicillin, chloramphenicol, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole. Thirty-two specimens (26%) yielded other Shigella species. Patients with S. dysenteriae type 1 were more likely than those with other Shigella infections to have abdominal pain, "lots of blood" in the stool, blood in the stool specimen examined by the interviewer, recent contact with a person with dysentery, or recent antimicrobial treatment. Thus, the seasonal increase in dysentery was due largely to multidrug-resistant S. dysenteriae type 1, clinical and epidemiologic features may predict such infection, and efforts to control this epidemic must focus on preventing transmission.

Entities:  

Mesh:

Year:  1994        PMID: 8169388     DOI: 10.1093/infdis/169.5.1035

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1.

Authors:  V Pozsgay; C Chu; L Pannell; J Wolfe; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Epidemic dysentery caused by Shigella dysenteriae type 1: a sentinel site surveillance of antimicrobial resistance patterns in Burundi.

Authors:  D Engels; T Madaras; S Nyandwi; J Murray
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

Review 3.  The best of times, the worst of times. The global challenge of antimicrobial resistance.

Authors:  F C Tenover
Journal:  Pharm World Sci       Date:  1995-09-22

4.  Shigella: A Highly Virulent and Elusive Pathogen.

Authors:  Mussaret Bano Zaidi; Teresa Estrada-García
Journal:  Curr Trop Med Rep       Date:  2014-06-01

Review 5.  Quinolone use in the developing world: state of the art.

Authors:  T E Tupasi
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Typing and characterization of mechanisms of resistance of Shigella spp. isolated from feces of children under 5 years of age from Ifakara, Tanzania.

Authors:  M M Navia; L Capitano; J Ruiz; M Vargas; H Urassa; D Schellemberg; J Gascon; J Vila
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

7.  Antimicrobial resistance of Shigella isolates causing traveler's diarrhea.

Authors:  J Vila; J Gascon; S Abdalla; J Gomez; F Marco; A Moreno; M Corachan; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  A look back at an ongoing problem: Shigella dysenteriae type 1 epidemics in refugee settings in Central Africa (1993-1995).

Authors:  Solen Kernéis; Philippe J Guerin; Lorenz von Seidlein; Dominique Legros; Rebecca F Grais
Journal:  PLoS One       Date:  2009-02-13       Impact factor: 3.240

Review 9.  Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005.

Authors:  P K Ram; J A Crump; S K Gupta; M A Miller; E D Mintz
Journal:  Epidemiol Infect       Date:  2007-08-09       Impact factor: 2.451

10.  Increasing antimicrobial resistance of Shigella isolates in Israel during the period 1984 to 1992.

Authors:  S Ashkenazi; M May-Zahav; J Sulkes; R Zilberberg; Z Samra
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.